VECTORIOUS MEDICAL TECHNOLOGIES LTD

Their core work

Vectorious is an Israeli medical technology SME developing V-LAP, an implantable cardiac monitoring device designed to enable daily, direct measurement of heart pressure in Heart Failure patients. Their core innovation is enabling physicians to track disease progression in real time and adjust treatment continuously — rather than relying on symptom-based visits. Both EU projects funded the same product through sequential phases: a feasibility study (SME-1, 2017) followed by full commercial development (SME-2, 2018–2020). They are a product-focused deeptech company, not a research group — their H2020 engagement was a funding vehicle for device development and commercialization.

What they specialise in

How they've shifted over time

Vectorious shows no meaningful shift in focus — both projects are the same product at different development stages. The 2017 SME-1 project was a feasibility and business case validation for V-LAP, while the 2018–2020 SME-2 project funded the full development, clinical validation, and market launch push. This is a single-product company executing a linear commercialization roadmap, not an organization diversifying its research agenda. The absence of keyword data and consortium partners confirms this: they were not building scientific networks, they were building a product.

Vectorious completed the EU SME Instrument pipeline by 2020; any future collaboration would likely involve clinical partners, hospital networks, or digital health integrators rather than further EU research funding.

How they like to work

Vectorious coordinated both projects independently — with zero recorded consortium partners — which is characteristic of SME Instrument projects where the company is the sole beneficiary. They do not appear to operate as a multi-partner consortium builder. Anyone seeking to collaborate with them would likely engage as a clinical validation site, distribution partner, or technology integrator, not as a co-researcher in a traditional EU project consortium.

Vectorious has no recorded H2020 consortium partners and collaborated with organizations in zero other countries through this dataset. Their EU engagement was entirely self-directed through the SME Instrument, which does not require or build a research network.

What sets them apart

Vectorious is one of the few non-European (Israeli) SMEs to successfully complete both phases of the EU SME Instrument for a cardiac implant, demonstrating both technical credibility and strong commercial positioning. Their V-LAP device addresses a specific, high-burden clinical gap — real-time left atrial pressure monitoring — that most remote cardiac monitoring solutions do not reach. For a consortium builder, they bring a validated, near-market medical device asset rather than early-stage research.

Highlights from their portfolio

• V-LAP (SME-1)
  The Phase 1 feasibility project (EUR 50,000, 2017) confirmed the business case and paved the way for the Phase 2 award, showing a deliberate and successful two-stage EU funding strategy.
• V-LAP (SME-2)
  The largest project at EUR 1,834,802 represents a full Phase 2 SME Instrument award — one of the more competitive EU funding instruments — validating both the technology and the commercial plan for a cardiac implant.